Global Gene Expression Analysis Market to Grow at 8.6% during 2024-2032, Impelled by High Demand for Personalized Medicines

According to the latest report by IMARC Group, titled "Gene Expression Analysis Market Report by Products & Services (Consumables, Instruments, Services), Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), DNA Microarray, Sanger Sequencing, and Others), Capacity (Low-to Mid-Plex Gene Expression Analysis, High-Plex Gene Expression Analysis), End-User (Pharmaceutical and Biotech Companies, Academic Institutes and Research Centers, and Others), and Region 2024-2032," the global gene expression analysis market reached a value of US$ 5.1 Billion in 2023. Gene expression analysis is extensively used across clinical, research and pharmaceutical settings to study individual genes, gene pathways or greater gene activity profiles. It extracts data from a gene and investigates the activity of the biological system from the coding gene to detect a change in the expression pattern. Consisting of processes, such as gene transcription, translation, post-translational protein modification and RNA splicing, this method is used for synthesizing functional gene products, including functional RNA species and protein products. The analysis of gene regulation also aids in the proper understanding of normal cellular processes to enhance the functionality of the existing diagnostic methods and assist in the development of new drugs. As a result, this method finds extensive applications in pharmacogenomics, biomarking and toxicology.


Global Gene Expression Analysis Market Trends:

The global market is primarily driven by the rising demand for personalized medicines, along with the increasing prevalence of chronic diseases. Understanding a patient’s unique molecular and genetic profile is crucial to the adoption of personalized medicines for the treatment of numerous ailments. Gene expression analysis aids in the modification of diagnostic methods, which vary according to the patient’s requirement. Moreover, declining prices of genetic sequencing has led to the growing adoption of sequencing in clinical applications, which is catalyzing the market growth. The low-cost availability of Next Generation Sequencing (NGS) technology, coupled with its high-speed performance and precise results, is also contributing to the market growth. Enhanced focus toward the adoption of advanced healthcare systems and modern diagnostics procedures, extensive research and development (R&D) in the field of gene therapy, and favorable government initiatives, including the Precision Medicine Initiative (PMI) by the United States Food and Drug Administration (US FDA) are some of the other factors that are projected to spur the market growth further. On account of the aforementioned factors, the market is anticipated to exhibit a CAGR of 8.6% during 2024-2032.

Market Summary:

• On the basis of the products & services, the market has been divided into consumables, instruments and services.
• Based on the technology, the market has been categorized into polymerase chain reaction (PCR), next generation sequencing (NGS), DNA microarray, sanger sequencing and others.
• On the basis of the capacity, the market has been bifurcated into low-to mid- and high-plex gene expression analysis.
• Based on the end-user, the market has been segregated into pharmaceutical and biotech companies, academic institutes and research centers and others.
• On the geographical front, the market has been classified into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico, Argentina, Colombia, Chile, Peru and others) and Middle East and Africa (Turkey, Saudi Arabia, Iran, the United Arab Emirates and others).
• The competitive landscape of the market has been examined with the detailed profiles of the key players operating in the market. Some of these players include Agilent Technologies, Inc., BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Eurofins GSC Lux SARL, F. Hoffmann-La Roche Ltd, GE Healthcare, Illumina, Inc., Oxford Gene Technology IP Limited, Pacific Biosciences of California Inc., PerkinElmer Inc., QIAGEN GmbH and Thermo Fisher Scientific Inc.

Report Scope:

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal